Xu R, Abraham S, McLarnon J G, Walker M J
Dept. of Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, Vancouver, Canada.
Life Sci. 1997;61(3):237-48. doi: 10.1016/s0024-3205(97)00379-2.
KC8851, a structural analogue of tedisamil, has previously been found to exhibit mixed blockade of K+ and Na+ currents in isolated rat ventricular myocytes. We have now investigated the antiarrhythmic actions of this compound in the anaesthetized rat and isolated rat heart. In the rat, KC8851, at concentrations as low as 0.2 micromol kg(-1) min(-1), widened the QT intervals of the ECG and prolonged the effective refractory period in a dose-dependent manner. Such actions were consistent with blockade of repolarizing K+ currents. At relatively higher doses (above 0.5 micromol kg(-1) min(-1)), KC8851 increased RSh amplitude suggesting blockade of Na+ currents. The compound was found to be effective against occlusion-induced arrhythmias at doses of 0.5 to 2 micromol kg(-1) min(-1). In isolated hearts, the effects of KC8851 on PR and QRS intervals were potentiated by elevated concentrations of K+ and H+. Overall, KC8851 was found to exhibit antiarrhythmic actions consistent with inhibition of both K+ and Na+ currents.
KC8851是替地沙米的一种结构类似物,此前已发现它在离体大鼠心室肌细胞中对钾离子(K⁺)和钠离子(Na⁺)电流表现出混合性阻滞作用。我们现在研究了该化合物在麻醉大鼠和离体大鼠心脏中的抗心律失常作用。在大鼠中,KC8851浓度低至0.2微摩尔/千克·分钟时,可使心电图的QT间期延长,并以剂量依赖方式延长有效不应期。这些作用与复极化钾离子电流的阻滞一致。在相对较高剂量(高于0.5微摩尔/千克·分钟)时,KC8851使RSh波幅增加,提示钠离子电流被阻滞。发现该化合物在剂量为0.5至2微摩尔/千克·分钟时对闭塞诱导的心律失常有效。在离体心脏中,高浓度的钾离子和氢离子可增强KC8851对PR间期和QRS间期的影响。总体而言,发现KC8851表现出与抑制钾离子和钠离子电流一致的抗心律失常作用。